Abstract: A modified conductive structure includes a conductive substrate and a polymer film disposed over a surface of the polymer film. A chemical bond exists between the polymer film and the conductive substrate, and the polymer film includes repeating units as shown below: wherein A is an antifouling molecule group; B is a sulfur-containing group or a nitrogen-containing group; R is a single bond or a first linking group; C is -L-E, wherein L is a second linking group, E is an enzyme unit; x and z are each independently 0 or an integer from 1 to 10000, and y is an integer from 1 to 10000; o is 0 or an integer from 1 to 50, and when o is an integer from 1 to 50, m and n are each independently 0 or an integer from 1 to 50.

Abstract: Antibodies and antigen-binding fragments that bind to TIGIT are disclosed. The disclosure further relates to methods and compositions for use in treating an immune-related disease (e.g., a cancer or an infection or infectious disease) by administering a composition disclosed herein.

Abstract: Antibodies and antigen-binding fragments that bind to TIGIT are disclosed. The disclosure further relates to methods and compositions for use in treating an immune-related disease (e.g., a cancer or an infection or infectious disease) by administering a composition disclosed herein.

Abstract: Antibodies and antigen-binding fragments that bind to TIGIT are disclosed. The disclosure further relates to methods and compositions for use in treating an immune-related disease (e.g., a cancer or an infection or infectious disease) by administering a composition disclosed herein.

Abstract: A modified conductive structure includes a conductive substrate and a polymer film disposed over a surface of the polymer film. A chemical bond exists between the polymer film and the conductive substrate, and the polymer film includes repeating units as shown below: wherein A is an antifouling molecule group; B is a sulfur-containing group or a nitrogen-containing group; R is a single bond or a first linking group; C is -L-E, wherein L is a second linking group, E is an enzyme unit; x and z are each independently 0 or an integer from 1 to 10000, and y is an integer from 1 to 10000; o is 0 or an integer from 1 to 50, and when o is an integer from 1 to 50, m and n are each independently 0 or an integer from 1 to 50.

Abstract: An in vitro method for screening a testing compound to evaluate its potential as a liver drug of the disclosure is provided. The method includes applying the testing compound to cells of an isolated human liver tumor cell line, named as ITRI-H28, measuring a cell viability of the cells and determining the effect of the testing compound on the cells by calculating a half maximal inhibitory concentration (IC50) of the testing compound.

Abstract: An in vitro method for screening a testing compound to evaluate its potential as a liver drug is provided. The method includes applying the testing compound to cells of an isolated human liver tumor cell line, named as ITRI-H16, measuring a cell viability of the cells and determining the effect of the testing compound on the cells by calculating a half maximal inhibitory concentration (IC50) of the testing compound.

Abstract: An isolated human liver tumor cell line is provided and is named as ITRI-H16, and which was deposited in the Food Industry Research and Development Institute with the accession number BCRC960432 on Nov. 7, 2011. A method of an agent screening is also provided. The method includes providing the isolated human liver tumor cell line ITRI-H16 and treating an interest compound to the ITRI-H16 cell line to determine an effect of the interesting compound on the ITRI-H16 cell line.

Abstract: An isolated human liver tumor cell line is provided, which was named as ITRI-H28 and deposited in the Food Industry Research and Development Institute with the accession number BCRC960457 on Dec. 14, 2012. A method of an agent screening is also provided. The method includes providing the isolated human liver tumor cell line ITRI-H28 and adding an interest compound into the ITRI-H28 cell line to determine an effect on the ITRI-H28 cell line.

Abstract: An artificial kidney (dialyzer) reprocessing system for washing used artificial kidneys includes a high-pressure water supply system providing RO water and chemical solutions for washing and sterilization so as to make artificial kidney (dialyzers) be reused. The feature of the device is that an ozone water device is connected to an high-pressure water supply system in parallel for providing the artificial kidney (dialyzer) reprocessing device ozone water for washing and sterilization. The problem of chemical residuals in the system can also be avoided.

Abstract: This utility model provides an object identification structure applicable for authentication, production control, and data retrieval, and such structure comprising an object with a printed page to be identified; and its feature is that there is a Radio Frequency Identification Integrated Circuit RFIDIC deposed at the appropriate position on the front printed page, and said RFIDIC further comprising a storage device for storing user's (or storing account) identification code, password, serial number and the like, working with a computer terminal connected to a set of wireless code reader interfaced with RS232 or RS485 for detection. Such arrangement can improve the control of the manufacturing procedure and attain the identification purpose.